SOURCE: InvestmentPitch

December 24, 2010 19:49 ET

Abattis Biologix Corporation (FLU - CNSX) Began Trading on the CNSX - InvestmentPitch.com Posts Video News Alert

VANCOUVER, BC--(Marketwire - December 24, 2010) -


Vancouver, British Columbia, December 24, 2010 - Abattis Biologix Corporation (FLU - CNSX) is the latest company to begin trading on the Canadian National Stock Exchange, better known as the CNSX.

To view the InvestmentPitch.com video news alert about Abattis Biologix, click here. If the link is unavailable, please visit www.InvestmentPitch.com and enter "Abattis" in the search bar.

On April 16, 2009, the company entered into an agreement with PRB Pharmaceuticals and Pacific Bio-Pharmaceuticals for the purchase of their interest in patents and intellectual property related to antiviral products designed to prevent avian influenza in humans and poultry. The company issued 25,000,000 common shares, assigned a value of $500,000, for this acquisition.

The Antiviral formulations were developed and designed to inhibit growth over multiple segments of the influenza virus life cycle - viral binding, encoding, replication, and release. To date, the company's research has shown the formulations to be highly effective in reducing the severity and duration of influenza illness symptoms in humans.

At present, the company is focused on refining and bringing to market a proprietary nutraceutical formulation of botanical agents with demonstrated ability to inhibit the growth of, and reduce the severity and duration of various strains of human influenza and other viral diseseases. Continuing research is being conducted at the Institute for Antiviral Research, Utah State University.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: InvestmentPitch via Thomson Reuters ONE

[HUG#1475649]

Contact Information

  • Contact:
    Abattis Biologix Corporation
    Gil Scneider
    604-484-5761
    Email Contact

    InvestmentPitch.com
    Barry Morgan, CFO
    604-684-5524
    Email Contact